Based in Taiwan, Primo aims to promote precision medicine for Taiwanese people with novel radiopharmaceuticals, and hopes to elevate Taiwan’s medical service quality in the prevention, diagnosis, and treatment of various diseases. Through novel radiopharmaceuticals with high specificity and sensitivity, in-vivo whole-body imaging of patients can be non-invasively provided and further used as a precision approach for physicians to increase the options available as tactics in disease management.
Compared to conventional imaging, Positron Emission Tomography (PET) provides superior molecular-level insights and comprehensive diagnostic data. This enables physicians to develop optimized treatment strategies, which is critical for the clinical management of cancer patients.
Cancer immunotherapy, molecular targeted therapy, and cell therapy are major trends of precision approaches in cancer treatment and unavoidably face therapeutic bottlenecks as cancer is always changeable and unpredictable.
A new integrated technology is necessary and warranted for the facilitation of current oncologic therapeutics as a revolutionary tool for precision medicine. This relies on advanced technology to evolve cancer management, and eventually to integrate all the benefits of various cancer treatment therapies.
One primary such new technology is the globally-applicable and appealing target-specific therapeutic mode, or radioligand theranostics, also known as RLT.
